NCT05849129TerminatedPhase 2
Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer: A Double Blind, Placebo Controlled, Phase II Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Reason given: Insufficient recruitment
Brief summary (registry, in English)
This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.
- Status (registry)
- Terminated
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 24 Apr 2023
- Start date
- 1 Oct 2024
- Primary completion date
- 24 Sept 2026
- Lead sponsor
- The Canadian College of Naturopathic Medicine
- Diseases
- Lung cancer
- NCT number
- NCT05849129
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received IVC within 6 months prior to randomization
- Currently taking insulin or warfarin
- Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
- Currently taking an investigational product or participation in an investigational study within the past 30 days
Other illness
- History of severe renal dysfunction or hemochromatosis
Lab values
- Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min
Other
- ECOG status greater than 2
- Biochemical deficiency in G6PD
- If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency
- Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating
Who the study is looking for
- Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer
- Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Ottawa Hospital | Ottawa | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.